Completed × Granulocyte Colony-Stimulating Factor × Breast × Clear all EMEG-ECDD
Phase NA Completed
97 enrolled
PRIMED
Phase 2 Completed
50 enrolled
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Phase 1 Completed
83 enrolled
Efficacy and Safety Study With MYL-1401H and Neulasta
Phase 3 Completed
193 enrolled
EMEG-E-01
Phase NA Completed
95 enrolled
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Phase 1 Completed
167 enrolled
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Phase 2 Completed
68 enrolled 10 charts
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
Phase 3 Completed
184 enrolled
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
Phase 2 Completed
50 enrolled 13 charts
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Phase 2 Completed
21 enrolled 11 charts
OTT14-03
Phase 4 Completed
142 enrolled
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
Phase 2 Completed
60 enrolled 11 charts
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Phase 3 Completed
60 enrolled
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
Phase 2 Completed
226 enrolled 8 charts
Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer
Phase 3 Completed
650 enrolled
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
Phase 2 Completed
62 enrolled
S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Phase 3 Completed
399 enrolled
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
Phase 2 Completed
16 enrolled
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
Phase 2 Completed
45 enrolled
Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12
Phase 2 Completed
80 enrolled
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer
Phase 1/2 Completed
21 enrolled
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer
Phase 3 Completed
478 enrolled
Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer
Phase 2 Completed
48 enrolled